Skip to main content
SpringerLink
Log in

Bloodstream infections: Epidemiology, pathophysiology and therapeutic perspectives

  • Review
  • Published:
Infection Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bone, R. C.: Sepsis, sepsis syndrome, multi-organ failure: a plea for comparable definitions (editorial). Ann. Intern. Med. 115 (1991) 457–469

    PubMed  CAS  Google Scholar 

  2. Balk, R. A., Bone, R. C.: The septic syndrome. Definition and clinical implications. Crit. Care Clin. 5 (1989) 1–8.

    PubMed  CAS  Google Scholar 

  3. Ujvari, S., Castelo, A., Salomão, R.: Evaluation of epidemiologic aspects and outcome of bloodstream infections, observed in 1985/1986 and 1992/1993, in a large teaching hospital of São Paulo, Brazil. 7th International Congress for Infectious Diseases, Hong Kong 1996, abstr. 22.022.

  4. Bone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M., Sibbald, W. J.: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American college of chest physicians/society of critical care medicine. Chest 101 (1992) 1644–1655.

    PubMed  CAS  Google Scholar 

  5. Pittet, D., Rangel-Frausto, S., Li, N., Tarara, D., Costigan, M., Rempe, L., Jebson, P., Wenzel, R. P.: Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med. 21 (1995) 299–301.

    Article  Google Scholar 

  6. McGowan, J. E., Barnes, M. W., Finland, M.: Bacteremia at Boston City Hospital: occurrence and mortality during 12 selected years (1935–1972), with special reference to hospital-acquired cases. J. Infect. Dis. 132 (1975) 316–335.

    PubMed  Google Scholar 

  7. McCabe, W. R., Jackson, G. G.: Gram-negative bacteremia I-etiology and ecology. Arch. Intern. Med. 110 (1962) 847–855.

    Google Scholar 

  8. Kreger, B. E., Craven, D. E., Carling, P. C., McCabe, W. R.: Gramnegative bacteremia III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am. J. Med. 68 (1980) 332–343.

    Article  PubMed  CAS  Google Scholar 

  9. Schaberg, D. R., Culver, D. H., Gaynes, R. P.: Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 91 (Suppl. 16) (1991) 72S-75S.

    Article  PubMed  CAS  Google Scholar 

  10. Weinstein, M. P., Reller, B., Murphy, J. R., Lichtenstein, K. A.: The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I—Laboratory and epidemiologic observations. Rev. Infect. Dis. 5 (1983) 35–53.

    PubMed  CAS  Google Scholar 

  11. Banergee, S. N., Emori, T. G., Culver, D. H., Gaynes, R. P., Jarvis, W. R., Horan, T., Edwards, J. R., Tolson, J., Henderson, T., Martone, W. J.: Secular trends in nosocomial primary bloodstream infections in the United States, 1980–1989. National nosocomial infections surveillance system. Am. J. Med. 91 (Suppl. 16) (1991) 86S-89S.

    Article  Google Scholar 

  12. Haug, J. B., Harthug, S., Kalager, T., Diagranes, A., Solberg, C. O.: Bloodstream infections at a Norwegian university hospital, 1974–1979 and 1988–1989: changing etiology, clinical features, and outcome. Clin. Infect. Dis. 19 (1994) 246–256.

    PubMed  CAS  Google Scholar 

  13. Pittet, D., Wenzel, R. P.: Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch. Intern. Med. 155 (1995) 1177–1184.

    Article  PubMed  CAS  Google Scholar 

  14. Pfaller, M. A.: Epidemiology of candidiasis. J. Hosp Infect. 30 (Suppl.) (1995) 329–338.

    Article  PubMed  Google Scholar 

  15. Haley, R. W.: Incidence and nature of endemic and epidemic nosocomial infections. In:Bennett, J. V., Brachman, P. S. (eds.): Hospital infections. Little, Brown, Boston 1979, pp. 359–374.

    Google Scholar 

  16. Garner, J. S., Jarvis, W. R., Emori, T. G., Horan, T. C., Hughes, J. M.: CDC definitions for nosocomial infections, 1988. Am. J. Infect. Control 16 (1988) 128–140.

    Article  PubMed  CAS  Google Scholar 

  17. Weinstein, M. P., Murphy, J. R., Reller, L. B., Lichtenstein, K. A.: The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. II—Clinical observations with special reference to factors influencing prognosis. Rev. Infect. Dis. 5 (1983) 54–70.

    PubMed  CAS  Google Scholar 

  18. Salomão, R., Wey, S. B., Pignatari, A. C., Castelo Filho, A.: Epidemiologia das bacteremias em hospital universitário/Epidemiology of bacteremias at a university hospital. Rev. Assoc. Med. Bras. 38 (1992) 62–66.

    PubMed  Google Scholar 

  19. Salomão, R., Wey, S. B., Pignatari, A. C., Castelo Filho, A.: Nosocomial and community-acquired bacteremia: variables associated with outcomes. Rev. Paul Med. 111 (1993) 456–461.

    PubMed  Google Scholar 

  20. Bryan, C. S., Hornung, C. A., Reynolds, K. L., Brenner, E. R.: Endemic bacteremia in Columbia, South Carolina. Am. J. Epidemiol. 123 (1986) 113–127.

    PubMed  CAS  Google Scholar 

  21. Fillice, G. A., Etta, L. L. V., Darby, C. P., Fraser, D. W.: Bacteremia in Charleston Country, South Carolina. Am. J. Epidemiol. 123 (1986) 128–136.

    Google Scholar 

  22. Bryant, R. E., Hood, A. F., Hood, C. E., Koenig, M. G.: Factors affecting mortality of gram-negative bacteremia. Arch. Intern. Med. 127 (1971) 120–128.

    Article  PubMed  CAS  Google Scholar 

  23. Kreger, B. E., Craven, D. E., McCabe, W. R.: Gram-negative bactermia IV. Re-evaluation of clinical features and treatment in 612 patients. Am. J. Med. 68 (1980) 344–355.

    Article  PubMed  CAS  Google Scholar 

  24. McCabe, W. R., Jackson, G. G.: Gram-negative bacteremia. II. Clinical, laboratory, and therapeutic observations. Arch. Intern. Med. 110 (1962) 92–100.

    Google Scholar 

  25. Mackowiak, P. A., Browne, R. H., Southern, P. M., Smith, J. W.: Polymicrobial sepsis: an analysis of 184 cases using log linear models. Am. J. Med. Sci. 280 (1980) 73–80.

    Article  PubMed  CAS  Google Scholar 

  26. Myerowitz, R. L., Medeiros, A. A., O'Brien, T. F.: Recent experience with bacillemia due to gram-negative organisms. J. Infect. Dis. 124 (1971) 239–246.

    PubMed  CAS  Google Scholar 

  27. Schekler, W. E.: Septicemia in a community hospital 1970 through 1973. JAMA 237 (1977) 1938–1941.

    Article  Google Scholar 

  28. Vaara, M., Nikaido, H.: Molecular, organization of bacterial outer membrane. In:Rietschel, E. T. (ed.) Handbook of endotoxin. Vol. I. Chemistry of endotoxin. Elsevier, Amsterdam 1984, pp. 1–45.

    Google Scholar 

  29. Rietschel, E. T., Brade, L., Schade, U., Seydel, U., Zähringer, U., Kusomoto, S.: Bacterial endotoxins: properties and structure of biologically active domains. In:Schrinner, E., Richmond, M. H., Seibert, G., Schwarz, U. (eds.). Surface structure of microorganisms and their interactions with the mammalian host. VCH, Basel 1988, pp. 1–42.

    Google Scholar 

  30. Rietschel, E. T., Schade, U., Jensen, M., Wollenweber, H. W., Lüderitz, O., Greisman, S. G.: Bacterial endotoxins: chemical structure, biological activity and role in septicaemia. Scand. J. Infect. Dis. Suppl. 31 (1982) 8–21.

    CAS  Google Scholar 

  31. Galanos, C., Lüderitz, O., Rietschel, E. T., Westphal, O.: Newer aspects of the chemistry and biology of bacterial lipopolysaccharides, with special reference to their lipid A component. Int. Rev. Biochem. 14 (1977) 239–335.

    CAS  Google Scholar 

  32. Galanos, C., Freudenberg, M. A., Hase, S., Jay, F., Ruschmann, H.: Biological activities and immunological properties of lipid A. In:Schlessinger, D. (ed.). Microbiology. American Society for Microbiology, Washington, D. C. 1977, pp. 269–276.

    Google Scholar 

  33. Galanos, C., Freudenberg, M. A., Krajewska, D., Takada, D., Georgiev, G., Bartholeyns, J.: Endotoxin: structural aspects and immunobiology of host responses. EOS. J. Immunol. Immunopharmacol. 6 (1986) 78–86.

    CAS  Google Scholar 

  34. Galanos, C., Freudenberg, M. A., Jay, F., Nerkar, D., Veleva, K., Brade, H., Strittmatter, W.: Immunogenic properties of lipid A. Rev. Infect. Dis. 6 (1984) 546–552.

    PubMed  CAS  Google Scholar 

  35. Galanos, C., Lüderitz, O., Rietschel, E. T., Westphal, O., Brade, H., Brade, L., Freudenberg, M. A., Schade, U., Imoto, M., Yoshimura, H., Kusunoto, S., Shiba, T.: Synthetic and naturalEscherichia coli-free lipid A express identical endotoxic activities. Eur. J. Biochem. 148 (1985) 1–5.

    Article  PubMed  CAS  Google Scholar 

  36. Freudenberg, M. A., Galanos, C.: The metabolic fate of endotoxins. In:Levin, J., Büller, H. R., ten Cate, J. W., van Deventer, S. J. H., Struk, A. (eds.): Bacterial endotoxins: pathophysiological effects, clinical significance, and pharmacological control. Alan R. Liss, Inc., New York 1988, pp. 63–75.

    Google Scholar 

  37. Freudenberg, M. A., Galanos, C.: Metabolism of LPSin vivo. In:Ryan, J. L., Morrison, D. C. (eds.) Bacterial endotoxic lipopolysaccharides. CRC Press, Boca Raton, Ann Arbor, London, Tokyo 1992, pp. 275–294.

    Google Scholar 

  38. Pajkrt, D., Doran, J. E., Koster, F., Learch, P., Arnet, B., van Deventer, S. J. H.: Reconstituted HDL (rHDL) reduces endotoxin-induced cytokine release and leukocyte activation in humans. Journal of Endotoxin Research 11 (Suppl. 1) (1996) 11.

    Google Scholar 

  39. Schumann, R. R., Leong, S. R., Flaggs, G. W., Gray, P. W., Wright, S. D., Mathison, J. C., Tobias, P. S., Ulevitch, R. J.: Structure and function of lipopolysaccharide binding protein. Science 249 (1990) 1429–1431.

    Article  PubMed  CAS  Google Scholar 

  40. Wright, S. D., Romos, R. A., Tobias, P. S., Ulevitch, R. J., Mathison, J. C.: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (1990) 1431–1433.

    Article  PubMed  CAS  Google Scholar 

  41. Frey, E. A., Miller, D. S., Jahr, T. G., Sundan, A., Bazil, V., Espevik, T., Finlay, B. B., Wright, S. D.: Soluble CD14 participates in the response of cells to lipopolysaccharide. J. Exp. Med. 176 (1992) 1665–1671.

    Article  PubMed  CAS  Google Scholar 

  42. Hailman, E., Lichenstein, H. S., Wurfel, M. M., Miller, D. S., Johnson, D. A., Kelley, M., Busse, L. A., Zukowski, M. M., Wright, S. D.: Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J. Exp. Med. 179 (1994) 269–277.

    Article  PubMed  CAS  Google Scholar 

  43. Gallay, P., Barras, C., Tobias, P. S., Calandra, T., Glauser, M. P., Heumann, D.: Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS. J. Infect. Dis. 170 (1994) 1319–1322.

    PubMed  CAS  Google Scholar 

  44. Sultzer, B. M., Goodman, G. W.: Characteristics of endotoxin-resistant low-responder mice. In:Schlessinger, D. (ed.): Microbiology. American society for microbiology. Washington, D.C. 1977, p. 304.

  45. Michalek, S., Moore, R. N., McGhee, J. R., Rosenstreich, D. L., Mergenhagen, S. E.: The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J. Infect. Dis. 141 (1980) 55–63.

    PubMed  CAS  Google Scholar 

  46. Freudenberg, M. A., Keppler, D., Galanos, C.: Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun. 51 (1986) 891–895.

    PubMed  CAS  Google Scholar 

  47. Galanos, C., Freudenberg, M. A., Coumbos, A., Matsuura, M., Lehmann, V., Bartholeyns, J.: Induction of lethality and tolerance by endotoxin are mediated by macrophages through tumor necrosis factor. In:Bonavida, B., Gifford, G. E., Kirchner, H., Old, L. J. (eds.). Tumor necrosis factor/cachectin and related cytokines. International Conference Tumor Necrosis Factor and Related Cytotoxins. Karger, Basel 1988, pp. 114–127.

    Google Scholar 

  48. Beutler, B., Cerami, A.: The common mediator of shock, cachexia, and tumor necrosis. Adv. Immunol. 42 (1988) 213–231.

    PubMed  CAS  Google Scholar 

  49. Beutler, B., Milsark, I. W., Cerami, A. C.: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229 (1985) 869–871.

    Article  PubMed  CAS  Google Scholar 

  50. Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wolpe, S., Milsark, I. W., Hariri, R. J., Fahey III, T. J., Zentella, A., Albert, J. D., Shires, G. T., Cerami, A.: Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470–474.

    Article  PubMed  CAS  Google Scholar 

  51. Lehmann, V., Freudenberg, M. A., Galanos, C.: Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med. 165 (1987) 657–663.

    Article  PubMed  CAS  Google Scholar 

  52. Waage, A., Halstensen, A., Espevik, T.: Association between tumor nectosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet i (1987) 355–357.

    Article  Google Scholar 

  53. Calandra, T., Baumgarten, J. D., Grau, G. E., Wu, M. M., Lambert, P. H., Schellekens, J., Verhoef, J., Glauser, M. P. andthe Swiss-Dutch J5 Immunoglobulin Study Group: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock. J. Infect. Dis. 161 (1980) 982–987.

    Google Scholar 

  54. De Groote, M. A., Martin, M. A., Densen, P., Pfaller, M. A., Wenzel, R. P.: Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 262 (1989) 249–251.

    Article  PubMed  Google Scholar 

  55. Marano, M. A., Fong, Y., Moldawer, L. L., Wei, H., Calvano, S. E., Tracey, K. J., Barie, P. S., Manogue, K., Cerami, A., Shires, G. T., Lowry, S. F.: Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg. Gynecol. Obstet. 170 (1990) 32–38.

    PubMed  CAS  Google Scholar 

  56. Waage, A.: Production and clearance of tumor necrosis factor in rats exposed to endotoxin and dexamethasone. Clin. Immunol. Immunopathol. 45 (1987) 348–355.

    Article  PubMed  CAS  Google Scholar 

  57. Michie, H. R., Manogue, K. R., Spriggs, D. R., Revhaug, A., O'Dwyer, S., Dinarello, C. A., Cerami, A., Wolff, S. M., Wilmore, D. W.: Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318 (1988) 1481–1486.

    Article  PubMed  CAS  Google Scholar 

  58. Hesse, D. G., Tracey, K. J., Fong, Y., Manogue, K. R., Palladino Jr., M. A., Cerami, A., Shires, T., Lowry, S. F.: Cytokine appearance in human endotoxemia and primate bacteremia. Surg. Gynecol. Obstet. 166 (1988) 147–153.

    PubMed  CAS  Google Scholar 

  59. Mathison, J. C., Wolfson, E., Ulevitch, R. J.: Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Invest. 81 (1988) 1925–1937.

    PubMed  CAS  Google Scholar 

  60. Han, J., Brown, T., Beutler, B.: Endotoxin-responsive sequence control cachectin/tumor necrosis factor biosynthesis at the translational level. J. Exp. Med. 171 (1990) 465–475.

    Article  PubMed  CAS  Google Scholar 

  61. Saribam, E., Imamura, K., Luebbers, R., Kufe, D.: Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J. Clin. Invest. 81 (1988) 1506–1510.

    Google Scholar 

  62. Collart, M. A., Belin, D., Vassalli, J. D., Kossodo, S., Vassalli, P.: Interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J. Exp. Med. 164 (1986) 2113–2118.

    Article  PubMed  CAS  Google Scholar 

  63. Hart, P. H., Vitti, G. F., Burgen, D. R., Whitty, G. A., Piccoli, D. S., Hamilton, J. A.: Potential antiinflammatory effects of interleukin 4: suppression of human monocyte TNF-α, interleukin-1 and prostaglandin E2. Proc. Natl. Acad. Sci. USA 86 (1989) 3803–3807.

    Article  PubMed  CAS  Google Scholar 

  64. Wong, H. L., Lotze, M. T., Wahl, L. M., Wahl, S. M.: Administration of recombinant IL-4 to humans regulates gene expression, phenotype, and function circulating monocytes. J. Immunol 148 (1992) 2118–2125.

    PubMed  CAS  Google Scholar 

  65. de Waal Malefyt, R., Abrams, J., Bennet, B., Figdor, C. G., de Vries, J. E.: Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174 (1991) 1209–1220.

    Article  PubMed  Google Scholar 

  66. Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M., O'Garra, A.: IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147 (1991) 3815–3822.

    PubMed  CAS  Google Scholar 

  67. Bogdan, C., Vodovotz, Y., Nathan, C.: Macrophage deactivation by interleukin-10. J. Exp. Med. 176 (1991) 1549–1555.

    Article  Google Scholar 

  68. Sher, A., Gazzinelli, R. T., Oswald, I. P., Clerici, M., Pearce, E. J., Berzofsky, J. A., Mosmann, T. R., James, S. L., Morse, H. C.: Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev. 127 (1992) 183–204.

    Article  PubMed  CAS  Google Scholar 

  69. Dinarello, C. A.: Interleukin-1 and its related cytokines. In:Sorg, C. (ed.). Macrophage-derived cell regulatory factors. Cytokines. Karger, Basel 1989, pp. 105–154.

    Google Scholar 

  70. Okusawa, S., Gelfand, J. A., Ikejima, T., Connoly, R. J., Dinarello, C. A.: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxigenase inhibition. J. Clin. Invest. 81 (1988) 1162–1172.

    PubMed  CAS  Google Scholar 

  71. Weinberg, R. J., Boyle, P., Meager, A., Guz, A.: Lipopolysaccharide, tumor necrosis factor, and interleukin-1 interact to cause hypotension. J. Lab. Clin. Med. 120 (1992) 205–211.

    PubMed  CAS  Google Scholar 

  72. Libby, P., Ordovas, J. M., Auger, K. R., Robbins, A. H., Birinyi, L. K., Dinarello, C. A.: Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am. J. Pathol. 124 (1986) 179–185.

    PubMed  CAS  Google Scholar 

  73. Pober, J. S.: Activation of vascular endothelium by tumor necrosis factor. Comparisons and interactions with other cytokines. In:Bonavida, B., Gifford, G. E., Kirchner, H., Old, L. J., (eds.), Tumor necrosis factor/cachectin and related cytokines. Karger, Basel 1988, pp. 74–81.

    Google Scholar 

  74. Fong, Y., Tracey, K. J., Lowry, S. F., Cerami, A.: Biology of cachectin. In:Sorg, C. (ed.). Macrophage-derived cell regulatory factors. Cytokines. Karger, Basel 1989, pp. 74–88.

    Google Scholar 

  75. Morrison, D. C., Ulevitch, R. J.: The effects of bacterial endotoxins on host mediation systems. Am. J. Pathol. 93 (1978) 527–617.

    Google Scholar 

  76. Freudenberg, N., Freudenberg, M. A., Guzman, J., Mittermayer, C. H., Bandara, K., Galanos, C.: Identification of endotoxin-positive cells in the rat lung during shock. Virchows Arch. 404 (1984) 197–211.

    Article  CAS  Google Scholar 

  77. Matsuura, M., Galanos, C.: Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection withSalmonella typhimurium. Infect. Immun. 58 (1990) 935–937.

    PubMed  CAS  Google Scholar 

  78. Bartholeyns, J., Freudenberg, M. A., Galanos, C.: Growing tumors induce hypersensitivity to endotoxin and tumor necrosis factor. Infect. Immun. 55 (1987) 2230–2233.

    PubMed  CAS  Google Scholar 

  79. Galanos, C., Freudenberg, M. A., Katschinski, T., Salomão, R., Mossmann, H., Kumazawa, Y.: Tumor necrosis factor and host response to endotoxin. In:Ryan, J. L., Morrison, D. C. (eds.). Bacterial endotoxic lipopolysaccharides. CRC Press 1992, pp. 75–104.

  80. Galanos, C., Freudenberg, M. A.: Mechanisms of endotoxin shock and endotoxin hypersensitivity. Immunobiology 187 (1993) 346–356.

    PubMed  CAS  Google Scholar 

  81. Katschinski, T., Galanos, C., Coumbos, A., Freudenberg, M. A.: Gamma-interferon mediatesPropionibacterium acnes-induced hypersensitivity to lipopolysaccharide in mice. Infec. Immun. 60 (1992) 1994–2001.

    CAS  Google Scholar 

  82. Galanos, C., Freudenberg, M. A., Reutter, W.: Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76 (1979) 5939–5943.

    Article  PubMed  CAS  Google Scholar 

  83. Johnston, C. A., Greisman, S. E.: Mechanisms of endotoxin tolerance. In:Hinshaw, L. B. (ed.). Handbook of endotoxin. Pathophysiology of endotoxin. Vol. 1, Elsevier, Amsterdam-New York-Oxford 1985, p. 359.

    Google Scholar 

  84. Greer, G. G., Rietschel, E. T.: Inverse relationship between the susceptibility of lipopolysaccharide (lipid-A)-pretreated mice to the hypothermic and lethal effect of lipopolysaccharide. Infec. Immun. 20 (1978) 366–374.

    CAS  Google Scholar 

  85. Dinarello, C. A., Bodel, P. T., Atkins, E.: The role of the liver in the production of fever and in pyrogenic tolerance. Trans. Assoc. Am. Physicians 81 (1968) 334–344.

    PubMed  CAS  Google Scholar 

  86. Schade, U., Rietschel, E. T.: The role of prostaglandins in endotoxic activities. Klin. Wochenschr. 60 (1982) 735–743.

    Article  Google Scholar 

  87. Sullivan, R., Gans, P. J., McCarroll, L. A.: The synthesis and secretion of granulocyte-monocyte colony-stimulating activity (CSA) by isolated human monocytes: kinetics of the response to bacterial endotoxin. J. Immunol. 130 (1983) 800–807.

    PubMed  CAS  Google Scholar 

  88. Zuckerman, S. H., Bendele, A. M.: Regulation of serum tumor necrosis factor in glucocorticoid-sensitive and-resistant rodent endotoxin shock models. Infec. Immun. 57 (1989) 3009–3013.

    CAS  Google Scholar 

  89. Madonna, G. S., Vogel, S. N.: Early endotoxin tolerance is associated with alterations in bone marrow-derived macrophage precursor pools. J. Immunol. 135 (1985) 3763–3771.

    PubMed  CAS  Google Scholar 

  90. Freudenberg, M. A., Galanos, C.: Induction of tolerance to lipopolysaccharide (LPS)-D-galactosamine lethality by pretreatment with LPS is mediated by macrophages. Infect. Immun. 56 (1988) 1352–1357.

    PubMed  CAS  Google Scholar 

  91. Vogel, S. N., Kaufman, E. N., Tate, M. D., Neta, R.: Recombinant interleukin-1a and recombinant tumor necrosis factor α synergizein vivo to induce early endotoxin tolerance and associated hematopoietic changes. Infect. Immun. 56 (1988) 2650–2657.

    PubMed  CAS  Google Scholar 

  92. Freudenberg, M. A., Galanos, C.: Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59 (1991) 2110–2115.

    PubMed  CAS  Google Scholar 

  93. Marks, J. D., Marks, C. B., Luce, J. M., Montgomery, A. B., Turner, J., Metz, C. A., Murray, J. F.: Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. Am. Rev. Respir. Dis. 141 (1990) 94–97.

    PubMed  CAS  Google Scholar 

  94. Titus, R. G., Sherry, B., Cerami, A.: Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J. Exp. Med. 170 (1989) 2097–2104.

    Article  PubMed  CAS  Google Scholar 

  95. Kindler, V., Sappino, A. P., Grau, G., Piguet, P. F., Vassali, P.: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56 (1989) 731–740.

    Article  PubMed  CAS  Google Scholar 

  96. Wu-Hsieh, B. A., Lee, G. S., Franco, M., Hofman, F. M.: Early activation of splenic macrophages by tumor necrosis factor alpha is important in determining the outcome of experimental histoplasmosis in mice. Infect. Immun. 60 (1992) 4230–4238.

    PubMed  CAS  Google Scholar 

  97. Nakane, A., Minagawa, T., Kohanawa, M., Chen, Y., Sato, H., Moriyama, M., Tsuruoka, N.: Interactions between endogenous gamma interferon and tumor necrosis factor in host resistance against primary and secondaryListeria monocytogenes infections. Infect. Immun. 57 (1989) 3331–3337.

    PubMed  CAS  Google Scholar 

  98. Hamilton, G., Hofbauer, S., Hamilton, B.: Endotoxin, TNF-α, interleukin-6 and parameters of the cellular immune system in patients with intraabdominal sepsis. Scand. J. Infect. Dis. 24 (1992) 361–368.

    PubMed  CAS  Google Scholar 

  99. Rigato, O., Ujvari, S., Castelo, A., Salomão, R.: Tumor necrosis factor alpha (TNF-α) and sepsis: evidence for a role in host defense. Infection 24 (1966) 314–318.

    Article  Google Scholar 

  100. Neu, H. C.: The crisis in antibiotic resistance. Science 257 (1992) 1064–1073.

    Article  PubMed  CAS  Google Scholar 

  101. Jacoby, G. A., Archer, G. L.: New mechanism of bacterial resistance to antimicrobial agents. N. Engl. J. Med. 324 (1991) 601–612.

    Article  PubMed  CAS  Google Scholar 

  102. Murray, B. E.: The life and times of theEnterococcus. Clin. Microbiol. Rev. 3 (1990) 46–65.

    PubMed  CAS  Google Scholar 

  103. Galanos, C., Lüderitz, O., Westphal, O.: Preparation and properties of antisera against the lipid A component of bacterial lipopolysaccharides. Eur. J. Biochem. 24 (1971) 116–122.

    Article  PubMed  CAS  Google Scholar 

  104. Tate, W. J., Douglas, H., Braude, A. I.: Protection against lethality ofE. coli endotoxin with “O” antiserum. Ann. N. Y. Acad. Sci. 133 (1966) 746–762.

    Article  PubMed  CAS  Google Scholar 

  105. Davis, C., Brown, K., Douglas, H., Tate, III, W. J., Braude, A. I.: Prevention of death from endotoxin with antisera: I. The risk of fatal anaphylaxis to endotoxin. J. Immunol. 102 (Suppl. 3) (1969) 563–729.

    PubMed  CAS  Google Scholar 

  106. Johns, M. A., McCabe, W. R.: Immunization with R mutantsSalmonella minnesota. II. Serological response to lipid A and the lipopolysaccharide of Re mutants. Infect. Immun. 17 (1977) 9–15.

    PubMed  CAS  Google Scholar 

  107. Greismann, S. E., Johnston, C. A.: Evidence against the hypothesis that antibodies to the inner core of lipopolysaccharides in antisera raised by immunization with enterobacterial deep-rough mutants confer broad-spectrum protection during gram-negative bacterial sepsis. (Review). J. Endotoxin Res. 4 (1997) 123–153.

    Google Scholar 

  108. Ziegler, F. J., Douglas, H., Braude, A. I.: Human antiserum for prevention of the local Shwartzman reaction and death from bacterial lipopolysaccharides. J. Clin. Invest. 52 (1973) 3236–3238.

    PubMed  CAS  Google Scholar 

  109. Ziegler, E. J., McCutchan, J. A., Douglas, H., Braude, A. I.: Prevention of lethalPseudomonas bacteremia with epimerase-deficientE. coli antiserum. Trans. Assoc. Am. Physicians 88 (1975) 101–108.

    PubMed  CAS  Google Scholar 

  110. Marks, M. I., Ziegler, E. J., Douglas, H., Corbeil, L. B., Braude, A. I.: Induction of immunity against lethalHaemophilus influenzae type b infection byEscherichia coli core lipopolysaccharide. J. Clin. Invest. 69 (1982) 742–749.

    Article  PubMed  CAS  Google Scholar 

  111. Chedid, L., Parant, M., Parant, F., Boyer, F.: A proposed mechanism for natural immunity to enterobacterial pathogens. J. Immunol. 100 (1968) 292–301.

    PubMed  CAS  Google Scholar 

  112. Ziegler, E. J., McCutchan, J. A., Fierer, J., Glauser, M. P., Sadoff, J. C., Douglas, H., Braude, A. I.: Treatment of gram-negative bacteremia and shock with human antiserum to a mutantEscherichia coli. N. Engl. J. Med. 307 (1982) 1225–1230.

    Article  PubMed  CAS  Google Scholar 

  113. Ng, A. K., Chen, C. L. H., Chang, C. M., Nowotny, A.: Relationship of structure to function in bacterial endotoxins: serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. J. Gen. Microbiol. 94 (1976) 107–116.

    PubMed  CAS  Google Scholar 

  114. Siber, G. R., Kania, S. A., Warren, H. S.: Cross-reactivity of rabbit antibodies to lipopolysaccharides ofEscherichia coli J5 and other gram-negative bacteria. J. Infect. Dis. 152 (1985) 954–964.

    PubMed  CAS  Google Scholar 

  115. Pennington, J. E., Menkes, E.: Type-specific vs cross-protective vaccination from gram-negative bacterial pneumonia. J. Infect. Dis. 144 (1981) 599–603.

    PubMed  CAS  Google Scholar 

  116. Calandra, T., Glauser, M. P., Schellekens, J., Verhoef, J., Swiss-Dutch Immunoglobulin Study Group: Treatment of gram-negative septic shock with human IgC antibody toEscherichia coli J5: a prospective, double-blind, randomized trial. J. Infect. Dis. 158 (1988) 312–319.

    PubMed  CAS  Google Scholar 

  117. Cometta, A., Baumgartner, J-D., Lee, M. L., Hanique, G., Glauser, M-P., The Intravenous Immunoglobulin Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high of postsurgical infection. N. Engl. J. Med. 327 (1992) 234–240.

    Article  Google Scholar 

  118. Teng, N. N. H., Kaplan, H. S., Hebert, J. M., Moore, C., Douglas, H., Wunderlich, A., Braude, A. I.: Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proc. Natl. Acad. Sci. USA 82 (1985) 1790–1794.

    Article  PubMed  CAS  Google Scholar 

  119. Parent, J. B., Gazzano-Santoro, H., Wood, D. M., Lim, E., Pruyne, P. T., Trown, P. H., Conlon, P. J.: Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharide. Circ. Shock 38 (1992) 63–73.

    PubMed  CAS  Google Scholar 

  120. Nelles, M. J., Niswander, C. A.: Mouse monoclonal antibodies reactive with J5 lipopolysaccharide exhibit extensive serological cross-reactivity with a variety of gram-negative bacteria. Infect. Immun. 46 (1984) 677–681.

    PubMed  CAS  Google Scholar 

  121. Miner, K. M., Manyak, C. L., Williams, E., Jackson, J., Jewell, M. Gammon, M. T., Ehrenfreund, C., Hayes, E., Callahan III, L. T., Zweerink, H., Sigal, N. H.: Characterization of murine monoclonal antibodies toEscherichia coli J5. Infect. Immun. 52 (1986) 56–62.

    PubMed  CAS  Google Scholar 

  122. Mutharia, L. M., Crockford, G., Bogard, W. C., Hancock, R. E. W.: Monoclonal antibodies specific forEscherichia coli J5 lipopolysaccharide: cross-reaction with other gram-negative bacterial species. Infect. Immun. 45 (1984) 631–636.

    PubMed  CAS  Google Scholar 

  123. Bogard Jr, W. C., Dunn, D. L., Abernethy, K., Kilgriff C., Kung, P. C.: Isolation and characterization of murine monoclonal antibodies specific for gram-negative bacterial lipopolysaccharide: association of cross-genus reactivity with lipid A specificity. Infect. Immun. 55 (1987) 899–908.

    PubMed  CAS  Google Scholar 

  124. Elkins, K., Metcalf, E. S.: Binding activity of a murine anti-lipid A monoclonal antibody. Infect. Immun. 48 (1985) 597–600.

    PubMed  CAS  Google Scholar 

  125. Appelmelk, B. J., Verweij-van Vught, A. M. J. J., Maaskant, J. J., Schouten, W. F., Thijs, L. G., McLaren, D. M.: Monoclonal antibodies detecting novel structures in the core region ofSalmonella minnesota lipopolysaccharide. FME 40 (1987) 71–74.

    CAS  Google Scholar 

  126. Pollack, M., Chia, J. K. S., Nancy, L. K., Miller, M., Guelde, G.: Specificity and cross-reactivity of monoclonal antibodies reactive with the core and lipid A regions of bacterial lipopolysaccharide. J. Infect. Dis. 159 (1989) 168–188.

    PubMed  CAS  Google Scholar 

  127. Greenman, R. L., Schein, R. M., Martin, M. A., Wenzel, R. P., Mac Intyre, N. R., Emmanuel, G., Chmel, H., Kohler, R. B., McCarthy, M., Plouffe, J.: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA sepsis study group. JAMA 266 (1991) 1097–1102.

    Article  PubMed  CAS  Google Scholar 

  128. Ziegler, E. J., Fisher, C. J., Jr., Sprung, C. L., Straube, R. C., Sadoff, J. C., Foulke, G. E., Wortel, C. H., Fink, M. P., Dellinger, R. P., Teng, N. M., Allan, I. E., Berger, H. J., Knatterud, G. L., Buglio, A. F., Smith, C. R., HA-1A Sepsis Study Group: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 324 (1991) 429–436.

    Article  PubMed  CAS  Google Scholar 

  129. Wenzel, R., Bone, R., Fein, A., Quenzer, R., Schentag, J., Gorelick, K. J., Wedel, N. I., Perl, T.: Results of a second double-blind, controlled tiral of antiendotoxin antibody E5 in gram-negative sepsis. Program and abstracts of the 31st Interscience Conference. Antimicrob. Agents Chemother. (1991) p. 294.

  130. McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., Smith, C. R., andthe CHESS Trial Study Group: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blin placebo-controlled trial. Ann. Intern. Med. 121 (1994) 1–5.

    PubMed  CAS  Google Scholar 

  131. Warren, H. S., Amato, S. F., Fitting, C., Black, K. M., Loiselle, P. M., Pasternack, M. S., Cavaillon, J. M.: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177 (1993) 89–97.

    Article  PubMed  CAS  Google Scholar 

  132. Baumgartner, J. D., Heumann, D., Gerain, J., Weinbreck, P., Grau, G. E., Glauser, M. P.: Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J. Exp. Med. 171 (1990) 889–896.

    Article  PubMed  CAS  Google Scholar 

  133. Di Padova, F. E., Brade, H., Barclay, G. R., Poxton, I. R., Liehl, E., Schuetze, E., Kocher, H. P., Ramsay, G., Schreier, H. M., McClelland, L. B., Rietschel, T. E.: A broadly cross-protective monoclonal antibody binding toEscherichia coli andSalmonella lipopolysaccharides. Infect. Immun. 61 (1993) 3863–3872.

    PubMed  Google Scholar 

  134. Saravolatz, L. D., Wherry, J. C., Spooner, C., Markowitz, N., Allred, R., Remick, D., Fournel, M., Pennington, J. E.: Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha. J. Infect. Dis. 169 (1994) 214–217.

    PubMed  CAS  Google Scholar 

  135. Abraham, E., Wunderink, R., Silverman, H., Perl, T. M., Nasraway, S., Levy, H., Bone, R., Wenzel, R. P., Balk, R., Allred, R.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter trial. TNF-alpha mab sepsis study group. JAMA 273 (1995) 934–941.

    Article  PubMed  CAS  Google Scholar 

  136. Bagby, G. J., Plessala, K. J., Wilson, L. A., Thompson, J. J., Nelson, S.: Divergent efficacy of antibody to tumor necrosis factor alpha in intravascular and peritonitis models of sepsis. J. Infect. Dis. 163 (1991) 83–88.

    PubMed  CAS  Google Scholar 

  137. Echtenacher, B., Falk, W., Männel, D. N., Krammer, P. H.: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145 (1990) 3762–3766.

    PubMed  CAS  Google Scholar 

  138. Lin, C. Y., Ku, W. L., Huang, T. P.: Serial peritoneal macrophage function studies in new established continuous ambulatory peritoneal dialysis patients. Am. J. Nephrol. 10 (1990) 368–373.

    Article  PubMed  CAS  Google Scholar 

  139. Mitov, I. G., Kropec, A., Just, H., Garotta, G., Galamos, C., Freudenberg, M.: Differential cytokine production in stimulated blood cultures from intensive care patients with bacterial infections. Infection 25 (1997) 206–212.

    Article  PubMed  CAS  Google Scholar 

  140. Fisher, C. J., Agosti, J. M., Opal, S. M., Lowry, S. F., Balk, R. A., Sadoff, J. C., Abraham, E., Schein, R. M., Benjamin, E.: Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The soluble TNF receptor sepsis study group. N. Engl. J. Med. 334 (1996) 1697–1702.

    Article  PubMed  CAS  Google Scholar 

  141. Jay, K. K., Dinghua, L., Steve, N., Warren, R. S., Stanley, G., Beutler, B.: Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J. Infect. Dis. 171 (1995) 570–575.

    Google Scholar 

  142. Pfeffer, K., Matsuyama, T., Kündig, T. M., Wakeham, A., Kishihara, K., Shahinian, A., Wiegmann, K., Ohashi, P. S., Krönke, M., Mak, T. W.: Mice deficient for the 55 kd tumor necrosis factor receptor succumb toL. monocytogenes infection. Cell 73 (1993) 457–467.

    Article  PubMed  CAS  Google Scholar 

  143. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N. Engl. J. Med. 317 (1987) 659–665.

    Article  Google Scholar 

  144. Bone, R. C., Fisher, C. J., Clemmer, T. P., Stotman, G. J., Metz, C. A., Balk, R. A.: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 317 (1987) 653–658.

    Article  PubMed  CAS  Google Scholar 

  145. Galanos, C., Frendenberg, M. A.: Tumor necrosis factor mediates endotoxin shock: the protective effects of antibodies and cortisone. In:Bonavida, B., Granger, G. (eds.): Tumor necrosis factor structure, mechanism of action, role in disease and therapy. Karger, Basel 1990, pp. 187–193.

    Google Scholar 

  146. Tobias, P. S., Mathison, J. C., Ulevitch, R. J.: A family of lipopolysaccharide binding proteins involved in response to gram-negative sepsis. J. Biol. Chem. 263 (1988) 13479–13481.

    PubMed  CAS  Google Scholar 

  147. Gazzano-Santoro, H., Parent, J. B., Grinna, L., Horwitz, A., Parsons, T., Thepfan, G., Elsbach, P., Weiss, J., Conlon, P. J.: High-affinity binding of the bactericidal/permeability-increasing protein and a recombinant amino-terminal fragment to the lipid A region of lipopolysaccharide. Infect. Immun. 60 (1992) 4754–4761.

    PubMed  CAS  Google Scholar 

  148. Kohn, F. R., Ammons, W. S., Horwitz, A., Grinna, L., Thepfan, G., Weickmann, J., Kung, A. H.: Protective effect of a recombinant amino-terminal fragment of bactericidal/permeability-increasing protein in experimental endotoxemia. J. Infect. Dis. 168 (1993) 1307–1310.

    PubMed  CAS  Google Scholar 

  149. Galanos, C., Roppel, J., Weckesser, J., Rietschel, E. T., Mayer, H.: Biological activities of lipopolysaccharides and lipid A from Rhodospirillaceae. Infect. Immun. 16 (1977) 407–412.

    PubMed  CAS  Google Scholar 

  150. Zuckerman, S. H., Qureshi, N.:In vivo inhibition of lipopolysaccharide-induced lethality and tumor necrosis factor synthesis byRhodobacter sphaeroides diphosphoryl lipid A is dependent on corticosterone induction. Infect. Immun. 60 (1992) 2581–2587.

    PubMed  CAS  Google Scholar 

  151. Carpati, C. M., Astiz, M. E., Saha, D. C., Rackow, E. C.: Diphosphoryl lipid A fromRhodopseudomonas sphaeroides induces tolerance to endotoxic shock in the rat. Crit. Care Med. 21 (1993) 753–758.

    Article  PubMed  CAS  Google Scholar 

  152. Pollok, J. S., Forstermann, U., Tracey, W. R., Nakane, M.: Nitric oxide synthase isozymes antibodies. Histochem. J. 27 (1995) 738–744.

    Google Scholar 

  153. Moncada, S., Palmer, R. M., Higgs, E. A.: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 43 (1991) 109–142.

    PubMed  CAS  Google Scholar 

  154. Cobb, J. P., Natanson, C., Hoffman, W. D., Lodato, R. F., Banks, S., Koev, C. A., Solomon, M. A., Elin, R. J., Hosseini, J. M., Danner, R. L.: N omega-amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J. Exp. Med. 176 (1992) 1175–1182.

    Article  PubMed  CAS  Google Scholar 

  155. Petros, A., Bennett, D., Vallance, P.: Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 338 (1991) 1557–1558.

    Article  PubMed  CAS  Google Scholar 

  156. Schneider, F., Lutun, P., Hasselmann, M., Stoclet, J. C., Temp, J. D.: Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med. 18 (1992) 309–311.

    Article  PubMed  CAS  Google Scholar 

  157. Arkovitz, M. S., Wispe, J. R., Garcia, V. F., Szabo, C.: Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J. Ped. Surg. 31 (1996) 1009–1015.

    Article  CAS  Google Scholar 

  158. Aranow, J. S., Zhuang, J., Wang, H., Larkin, V., Smith, M., Fink, M. P.: A selective inhibitor of inducible in nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: comparison with two nonselective strategies. Shock 5 (1996) 116–121.

    Article  PubMed  CAS  Google Scholar 

  159. Fukatsu, K., Saito, H., Fukushima, R., Inoue, T., Lin, M. T., Inaba, T., Muto, T.: Detrimental effects of a nitric oxide synthase inhibitor (N-omega-nitro-L-arginine-ester) in a murine sepsis model. Arch. Surg. 130 (1995) 410–414.

    PubMed  CAS  Google Scholar 

  160. Tracey, W. R., Nakane, M., Basha, F., Carter, G.:In vivo pharmacological evaluation of two novel type II (inducible) nitric oxide synthase inhibitors. Can. J. Physiol. Pharmacol. 73 (1995) 665–669.

    PubMed  CAS  Google Scholar 

  161. Hailman, E., Vasselon, T., Kelley, M., Busse, L. A., Hu, M. C.-T., Lichenstein, H. S., Dettmers, P. A., Wright, S. D.: Stimulation of macrophages and neutrophils by complexes of lipopolysaccharide and soluble CD14. J. Immunol. 156 (1993) 4384–4390.

    Google Scholar 

  162. Ziegler-Heitbrock, H. W. L., Ulevitch, R. J.: CD14: cell surface receptor and differentiation marker. Immunol. Today 14 (1993) 121–125.

    Article  PubMed  CAS  Google Scholar 

  163. Heumann, D., Gallay, P., Barras, C., Zaech, P., Ulevitch, R. J., Tobias, P. S., Glauser, M.-P., Baumgartner, J. D.: Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J. Immunol. 148 (1992) 3505–3512.

    PubMed  CAS  Google Scholar 

  164. Jack, R. S., Fan, X., Bernheiden, M., Rune, G., Ehler, M., Weber, A., Kirsch, G., Mentel, R., Fürll, B., Freudenberg, M. A., Schmitz, G., Stelter, F., Schütt, C.: Lipopolysaccharide-binding protein is requiredin vivo to combat a gram-negative bacterial infection. Nature 389 (1997) 742–745.

    Article  PubMed  CAS  Google Scholar 

  165. Freudenberg, M. A., Gumenscheimer, M., Jack, R., Merlin, T., Schütt, C., Galanos, C.: A strict requirement for LBP in the TNF-alpha hypersensitivity-response ofPropionibacterium acnes-sensitized mice to LPS. J. Endotoxin Research 4 (1997) 357–361.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Div. of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 740, CEP: 04023-900, São Paulo, SP, Brazil

    R. Salomão M. D., O. Rigato M. D. & A. C. Pignatari M. D.

  2. Max-Planck-Institut für Immunbiologie, Stübeweg 51, D-79108, Freiburg i. Br., Germany

    M. A. Freudenberg M. D. &  C. Galanos Ph. D.

Authors
  1. R. Salomão M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. Rigato M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. C. Pignatari M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. A. Freudenberg M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Galanos Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Salomão, R., Rigato, O., Pignatari, A.C. et al. Bloodstream infections: Epidemiology, pathophysiology and therapeutic perspectives. Infection 27, 1–11 (1999). https://doi.org/10.1007/BF02565163

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02565163

Keywords

Search

Navigation